【摘要】 目的：探究上皮性卵巢癌(EOC)患者血清增殖诱导配体(APRIL)、半乳糖凝集素-1(Gal-1)水平与临床特征和预后的关系。方法：选取2019年10月—2021年10月在本院确诊的EOC患者103例作为EOC组，108例健康体检者作为对照组(Control组)。根据2年预后情况，将EOC患者分为生存组(55例)和死亡组(48例)。收集患者临床特征相关资料；酶联免疫吸附试验(ELISA)检测血清APRIL、Gal-1水平；Kaplan-Meier法分析血清APRIL、Gal-1水平与EOC患者2年预后的关系；Cox比例风险回归模型分析EOC患者2年预后的影响因素。结果：与Control组相比，EOC组患者血清APRIL、Gal-1水平均显著增加(P<0.05)。肿瘤低分化、淋巴转移、FIGO分期为Ⅲ～Ⅳ期的APRIL、Gal-1高水平患者比例显著高于肿瘤中高分化、无淋巴转移、FIGO分期为Ⅰ～Ⅱ期的APRIL、Gal-1高水平患者比例(P<0.05)。血清APRIL高水平患者2年生存率低于APRIL低水平患者(Log Rankχ~2=18.523,P<0.05);血清Gal-1高水平患者2年生存率低于Gal-1低水平患者(Log Rankχ~2=12.998,P<0.05)。死亡组低分化、淋巴转移、FIGO分期为Ⅲ～Ⅳ期、APRIL和Gal-1高水平患者比例显著高于生存组(P<0.05)。分化程度、淋巴转移、FIGO分期、APRIL、Gal-1是EOC患者2年内死亡的独立危险因素(P<0.05)。结论：EOC患者血清APRIL、Gal-1水平上调，其水平与分化程度、淋巴转移、FIGO分期及预后相关。更多还原

【Abstract】 Objective: To investigate the relationship between serum levels of proliferation inducing ligand(APRIL) and Galectin-1(Gal-1) in patients with epithelial ovarian cancer(EOC) and clinical characteristics and prognosis. Methods: A total of 103 EOC patients diagnosed in our hospital from October 2019 to October 2021 were regarded as the EOC group, and 108 healthy individuals were collected as the Control group. According to the 2-year prognosis, EOC patients were separated into a survival group(55 cases) and a death group(48 cases). Data related to the clinical characteristics of patients were collected.Enzyme linked immunosorbent assay(ELISA) was applied to detect serum APRIL and Gal-1 levels. Kaplan-Meier method was applied to analyze the relationship between serum APRIL and Gal-1 levels and the 2-year prognosis of EOC patients.Cox proportional risk regression model was applied to analyze the influencing factors of 2-year prognosis in EOC patients. Results: Compared with the Control group, the serum APRIL and Gal-1 levels in the EOC group were obviously higher(P<0.05). The proportions of high APRIL and Gal-1 levels in patients with poorly differentiated tumors, lymph node metastasis, and FIGO stage Ⅲ～Ⅳ were obviously higher than those APRIL and Gal-1 levels in patients with well differentiated tumors, no lymph node metastasis, and FIGO stage Ⅰ～Ⅱ(P<0.05). The 2-year survival rate of patients with high serum APRIL level was lower than that of patients with low serum APRIL level(Log Rank χ~2=18.523, P<0.05); the 2-year survival rate of patients with high serum Gal-1 level was lower than that of patients with low serum Gal-1 level(Log Rank χ~2=12.998, P<0.05). The proportions of low differentiation, lymph node metastasis, FIGO staging of stage Ⅲ～Ⅳ, and high levels of APRIL and Gal-1 in the death group were obviously higher than those in the survival group(P<0.05). Differentiation degree, lymph node metastasis, FIGO staging, APRIL, and Gal-1 were independent risk factors for death within 2-year in EOC patients(P<0.05). Conclusion: The serum APRIL and Gal-1 levels in EOC patients are up-regulated, and their levels are related to the degree of differentiation, lymph node metastasis, FIGO staging, and prognosis.更多还原